Signet Therapeutics (Shenzhen) Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Signet Therapeutics (Shenzhen) Co., Ltd. - overview
Established
2020
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2020 and based in Shenzhen, China, Signet Therapeutics (Shenzhen) Co. , Ltd. is a healthcare technology company that provides cancer innovative prescription drugs. The company is mainly involved in the field of chemical pharmacy, targeted drugs, medical, and health.
The founder and CEO Dr. Haisheng Zhang graduated from Harvard University and worked at the Dana-Farber cancer institute. It has new drug research and development center in Shenzhen and Boston. In January 2026, Signet Therapeutics (Shenzhen) Co.
, Ltd. raised CNY 80 million in series A funding from returning investors Tiantu Capital, BOCG, Green Pine Capital Partners, XtalPi Inc. and new investor Intelligent collaboration. The company's main business is research and development of immune cell technology, biomedical technology, and cancer innovative prescription drugs.
The company has a self-developed disease model platform that uses in the field of stomach cancer, bowel cancer, lung cancer, and breast cancer. The company’s revenue is generated by providing targeted cancer drugs. The series A funding will be primarily used to advance the global Phase II clinical trial of the company's first pipeline drug, SIGX1094, and to support the IND filing and Phase I clinical trial of its second pipeline drug, SIGX2649.
Current Investors
Tiantu Capital, Leaguer Group, Sky 9 Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.